ACRX logo

AcelRx Pharmaceuticals (ACRX) Stock

Profile

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Country:

United States

IPO:

11 February 2011

Indexes:

Not included

Website:

http://www.acelrx.com

Description:

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$651.00 K(-63.24% YoY)

Annual EPS

-

PE Ratio

-

Annual ROE

-130.43%

Annual Debt To Equity

-

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 14, 2022

Recent annual earnings:

Mar 10, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 26, 2022

Analyst ratings

Recent major analysts updates

02 Oct '23 Alliance Global Partners
Buy
25 Sept '23 HC Wainwright & Co.
Buy
18 Aug '23 HC Wainwright & Co.
Buy
14 Mar '22 HC Wainwright & Co.
Neutral
17 Aug '21 HC Wainwright & Co.
Buy
13 Aug '20 Credit Suisse
Underperform
20 July '20 Credit Suisse
Underperform
17 Mar '20 H.C. Wainwright
Buy
11 Nov '19 Credit Suisse
Neutral
24 Apr '19 B. Riley FBR
Buy

Screeners with ACRX included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$262.40
ACRX price is currently at an all-time high

Price Analysts Target

$4.63
ACRX price is currently equal to the consensus analysts' forecast

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

-87.98%
ACRX annual revenue is down -87.98% over the past 3 years

Annual Revenue Estimate

$1.36 M
ACRX annual revenue is currently -52.13% lower than the consensus analysts' forecast

Annual Net Income 3-Year Change

+54.44%
ACRX annual net profit is up +54.44% over the past 3 years

Annual Operating Profit

-$16.89 M
ACRX annual operaing income is -$16.89 million

Annual Operating Profit 3-Year Change

+58.77%
ACRX annual operaing income is up +58.77% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-130.43%
ACRX annual return on equity is -130.43%

Annual ROA

-90.20%
ACRX annual return on assets is -90.20%

Annual EBIT

-$10.15 M
ACRX annual earnings before interest & taxes is -$10.15 million

Annual EBITDA

-$9.84 M
ACRX annual earnings before interest, taxes, depreciation & amortization is -$9.84 million

Annual Interest Coverage Ratio

-75.77
ACRX annual interest coverage ratio is -75.77

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Current Ratio

2.56
ACRX annual current ratio is 2.56

Annual Total Assets

$20.39 M
ACRX annual total assets is $20.39 million

Annual Current Assets

$11.56 M
ACRX annual total current assets is $11.56 million

Annual Total Liabilities

$6.29 M
ACRX annual total liabilities is $6.29 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+54.57%
ACRX annual cash flow from operations is up +54.57% over the past 3 years

Annual CFI 3-Year Change

-101.55%
ACRX annual cash flow from investing activities is down -101.55% over the past 3 years

Annual CFF 3-Year Change

-79.56%
ACRX annual cash flow from financing activities is down -79.56% over the past 3 years

Annual CAPEX

$100.00 K
ACRX annual capital expenditures is $100.00 thousand

Annual CAPEX 3-Year Change

-94.61%
ACRX annual capital expenditures is down -94.61% over the past 3 years

Annual FCF

-$17.59 M
ACRX annual free cash flow is -$17.59 million

Annual FCF 3-Year Change

+56.41%
ACRX annual free cash flow is up +56.41% over the past 3 years

Institutional Ownership

Similar stocks

AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2023 Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2023 Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2023 Earnings Call Transcript
ACRX
Seeking Alpha09 November 2023

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pam Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Thomas Yip - H.C. Wainwright & Co. James Molloy - Alliance Global Partners Operator Welcome to the AcelRx third quarter 2023 financial results conference call.

AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript
ACRX
Seeking Alpha10 August 2023

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief Financial Officer Vince Angotti – Chief Executive Officer Pam Palmer – Founder and Chief Medical Officer Conference Call Participants Thomas Yip – H.C. Wainwright Laura Suriel – Alliance Global Operator Welcome to the AcelRx Second Quarter 2023 Financial Results Conference Call.

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
ACRX
Zacks Investment Research10 August 2023

AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $1.20 per share a year ago.

AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
ACRX
Zacks Investment Research10 May 2023

AcelRx Pharmaceuticals (ACRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $1.20 per share a year ago.

AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript
AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript
AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript
ACRX
Seeking Alpha30 March 2023

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Welcome to the AcelRx 2022 Full Year and Fourth Quarter Financial Results Conference Call. This call is being webcast live via the Events page on the Investors section of AcelRx's website at www.acelrx.com.

AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
ACRX
Zacks Investment Research30 March 2023

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

FAQ

  • What is the primary business of AcelRx Pharmaceuticals?
  • What is the ticker symbol for AcelRx Pharmaceuticals?
  • Does AcelRx Pharmaceuticals pay dividends?
  • What sector is AcelRx Pharmaceuticals in?
  • What industry is AcelRx Pharmaceuticals in?
  • What country is AcelRx Pharmaceuticals based in?
  • When did AcelRx Pharmaceuticals go public?
  • Is AcelRx Pharmaceuticals in the S&P 500?
  • Is AcelRx Pharmaceuticals in the NASDAQ 100?
  • Is AcelRx Pharmaceuticals in the Dow Jones?
  • When was AcelRx Pharmaceuticals's last earnings report?
  • When does AcelRx Pharmaceuticals report earnings?
  • Should I buy AcelRx Pharmaceuticals stock now?

What is the primary business of AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

What is the ticker symbol for AcelRx Pharmaceuticals?

The ticker symbol for AcelRx Pharmaceuticals is NASDAQ:ACRX

Does AcelRx Pharmaceuticals pay dividends?

No, AcelRx Pharmaceuticals does not pay dividends

What sector is AcelRx Pharmaceuticals in?

AcelRx Pharmaceuticals is in the Healthcare sector

What industry is AcelRx Pharmaceuticals in?

AcelRx Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is AcelRx Pharmaceuticals based in?

AcelRx Pharmaceuticals is headquartered in United States

When did AcelRx Pharmaceuticals go public?

AcelRx Pharmaceuticals's initial public offering (IPO) was on 11 February 2011

Is AcelRx Pharmaceuticals in the S&P 500?

No, AcelRx Pharmaceuticals is not included in the S&P 500 index

Is AcelRx Pharmaceuticals in the NASDAQ 100?

No, AcelRx Pharmaceuticals is not included in the NASDAQ 100 index

Is AcelRx Pharmaceuticals in the Dow Jones?

No, AcelRx Pharmaceuticals is not included in the Dow Jones index

When was AcelRx Pharmaceuticals's last earnings report?

AcelRx Pharmaceuticals's most recent earnings report was on 14 November 2022

When does AcelRx Pharmaceuticals report earnings?

The date for AcelRx Pharmaceuticals's next earnings report has not been announced yet

Should I buy AcelRx Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions